Very Low-Dose Intratympanic Gentamicin in Ménière’s Disease
Background: Intratympanic gentamicin is widely used for vertigo control in patients with Ménière’s disease refractory to conservative therapy. Dose titration aims to achieve vestibular ablation while preserving cochlear function. Aim: To evaluate the efficacy and safety of a very low-dose intratympanic gentamicin protocol in patients with endolymphatic hydrops and disabling vertigo. Methods: This prospective clinical case series included 27 patients with definite Ménière’s disease who failed medical treatment. Gentamicin sulfate (5 mg/mL) was administered every 12 hours through a tympanostomy tube. Treatment was discontinued at the first subjective sign of ototoxicity. Mean duration of treatment approximately 9 days. Follow-up ranged from 6 months to 4 years. Primary outcome was vertigo control. Secondary outcomes included hearing level, tinnitus, and vestibular function. Results: Vertigo control was achieved in 96% (26/27) of patients. Hearing was preserved or improved in 92% (25/27). Tinnitus was unchanged or improved in 23 patients and worsened in four. Vestibular function was unchanged in four patients, reduced in 17, and absent in six. Conclusions: Very low-dose intratympanic gentamicin provides good vertigo control with a high rate of hearing preservation. It represents a simple, and cost-effective alternative to destructive surgical procedures in selected patients with refractory Ménière’s disease. Received: 23 June 2026 │ Accepted: 29 October 2026 │ Published: 20 November 2026
Authors
- Trifon Kiratzidis
- Evis Bendo
Institutions
- Mother Teresa Hospital (AL)
- Veria General Hospital (GR)
Publication Details
- Journal
- Interdisciplinary Journal of Research and Development
- Published
- 2026-11-20
- DOI
- https://doi.org/10.56345/ijrdv13n313
- Primary Topic
- Vestibular and auditory disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00